Parenteral and Inhaled Prostanoid Therapy in the Treatment of Pulmonary Arterial Hypertension

被引:35
|
作者
McLaughlin, Vallerie V. [1 ]
Palevsky, Harold I. [2 ]
机构
[1] Univ Michigan Hosp & Hlth Syst, Ctr Cardiovasc, Pulm Hypertens Program, Ann Arbor, MI 48109 USA
[2] Penn Presbyterian Med Ctr, Pulm Vasc Dis Program, Philadelphia, PA 19104 USA
关键词
Epoprostenol; Iloprost; Inhaled therapy; Intravenous therapy; Parenteral therapy; Prostacyclins; Prostanoids; Treprostinil; CONTINUOUS INTRAVENOUS EPOPROSTENOL; LONG-TERM TREATMENT; CONTINUOUS SUBCUTANEOUS INFUSION; BLOOD-STREAM INFECTIONS; PROSTACYCLIN ANALOG; CONTROLLED-TRIAL; PLATELET-AGGREGATION; AEROSOLIZED ILOPROST; IV EPOPROSTENOL; SMOOTH-MUSCLE;
D O I
10.1016/j.ccm.2013.09.003
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Since continuous IV epoprostenol was approved in the U.S., parenteral prostanoid therapy has remained the gold standard for the treatment of patients with advanced pulmonary arterial hypertension (PAH). Prostanoid agents can be administered as continuous intravenous infusions, as continuous subcutaneous infusions and by intermittent nebulization therapy. This article presents data from clinical trials of available prostanoid agents, and their varied routes of administration. The varied routes of administration allow for the incremental use of this class of agents in advanced PAH, and if PAH progresses. Prostanoids will remain a major component of PAH therapy for the foreseeable future.
引用
收藏
页码:825 / +
页数:17
相关论文
共 50 条
  • [1] Successful transition from parenteral to inhaled prostanoid therapy in pulmonary arterial hypertension
    Smith, Kelly J.
    Mallory, George B.
    [J]. CHEST, 2006, 130 (04) : 239S - 239S
  • [2] Inhaled prostanoid therapy for pulmonary arterial hypertension - a promise unfulfilled?
    Ramani, Gautam V.
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (07) : 923 - 925
  • [3] Longitudinal Effects of Initiation of Parenteral Prostanoid Therapy for the Treatment of Pulmonary Arterial Hypertension, The Pulmonary Hypertension Association Registry
    Pan, H.
    Argula, R. G.
    Badesch, D. B.
    De Marco, T.
    Elwing, J. M.
    Grinnan, D.
    Lammi, M. R.
    Mazimba, S.
    Raval, A. A.
    Ryan, J. J.
    Shlobin, O. A.
    Thenappan, T.
    Mathai, S. C.
    Leary, P. J.
    Al-Naamani, N.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [4] Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
    Kimmig, Lucas M.
    Liao, Chuanhong
    Bag, Remzi
    [J]. LUNG, 2020, 198 (01) : 53 - 58
  • [5] Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension
    Lucas M. Kimmig
    Chuanhong Liao
    Remzi Bag
    [J]. Lung, 2020, 198 : 53 - 58
  • [6] Prostanoid therapy for pulmonary arterial hypertension
    Strauss, Wayne L.
    Edelman, Jeffrey D.
    [J]. CLINICS IN CHEST MEDICINE, 2007, 28 (01) : 127 - +
  • [7] Prostanoid therapy for pulmonary arterial hypertension
    Badesch, DB
    McLaughlin, VV
    Delcroix, M
    Vizza, CD
    Olschewski, H
    Sitbon, O
    Barst, RJ
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (12) : 56S - 61S
  • [8] Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension
    Ataya, Ali
    Somoracki, Angelina
    Cope, Jessica
    Alnuaimat, Hassan
    [J]. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2016, 40 : 39 - 43
  • [9] Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?
    Michele Correale
    Deodata Montrone
    Riccardo Ieva
    Matteo Di Biase
    Natale Daniele Brunetti
    [J]. Clinical Research in Cardiology, 2013, 102 : 391 - 393
  • [10] Ivabradine in pulmonary arterial hypertension: can we delay the need for parenteral prostanoid therapy?
    Correale, Michele
    Montrone, Deodata
    Ieva, Riccardo
    Di Biase, Matteo
    Brunetti, Natale Daniele
    [J]. CLINICAL RESEARCH IN CARDIOLOGY, 2013, 102 (05) : 391 - 393